Abstract
ObjectiveTo estimate the cost-effectiveness of adalimumab plus methotrexate (MTX) versus MTX monotherapy in early, aggressive rheumatoid arthritis (RA) when explicitly modelling short-term (reversible) and long-term (irreversible, ie, joint damage) disease...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have